Drug Profile


Alternative Names: CCRG-81045; MB-39831; MK-7365; NSC-362856; RP-46161; SCH-52365; Temodal; Temodar

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Cancer Research UK
  • Developer Merck & Co; Schering-Plough; Stanford University; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Small molecules; Triazenes
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Anaplastic astrocytoma; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic astrocytoma; Glioma; Malignant melanoma
  • Phase II Acute myeloid leukaemia
  • No development reported Myelodysplastic syndromes; Non-small cell lung cancer; Small cell lung cancer
  • Discontinued Non-Hodgkin's lymphoma; Prostate cancer; Sarcoma

Most Recent Events

  • 14 Jul 2016 Medivation plans a phase II trial for Endometrial cancer in USA (NCT02836028)
  • 16 Jun 2016 M.D. Anderson Cancer Center completes a phase II trial in Malignant melanoma (Late-stage disease, Neoadjuvant therapy, Monotherapy, Combination therapy) in USA (PO) (NCT00525031)
  • 12 Apr 2016 Stanford University and Merck suspend enrolment in a phase II trial for Acute myeloid leukaemia (Combination therapy, Newly diagnosed, Second-line therapy or greater) in USA (NCT01550224)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top